Author Archives : Editorial Team

Home  >>  Author : Editorial Team

DKFZ: New research project on age-related diseases

On January 16, 2018, Posted by , In News, With Comments Off on DKFZ: New research project on age-related diseases

The German Cancer Research Center and the Helmholtz Zentrum München will be coordinating a project called “Aging and Metabolic Programming”, or AMPro for short, over the next three years. All centers of the Helmholtz Health Research Section will be involved with the aim of exploring innovative prevention and treatment approaches…

DKFZ: Communicative peroxidases

On January 16, 2018, Posted by , In News, With Comments Off on DKFZ: Communicative peroxidases

Reactive oxygen species (ROS) are oxidizing molecules that are produced, for example, in cellular respiration and in inflammatory processes. They can damage cellular components and the genetic material. On the other hand, oxidizing molecules, particularly so-called peroxides, also play a role in cellular signal transmission. Scientists from the German Cancer…

EY schließt sich mit Strategieberater OC&C Deutschland zusammen

On January 12, 2018, Posted by , In News, With Comments Off on EY schließt sich mit Strategieberater OC&C Deutschland zusammen

EY baut internationale Strategieberatung EY-Parthenon in Deutschland und Europa aus Komplettes OC&C-Deutschland-Team zu EY-Parthenon gewechselt Weiterer wichtiger Schritt beim Ausbau der Strategieberatung in Europa Stuttgart, 11. Januar 2018. Das Prüfungs- und Beratungsnetzwerk EY (Ernst & Young) baut seine internationale Strategieberatung unter der Marke EY-Parthenon kräftig weiter aus: Die Ernst &…

Kompetenzzentrum CeMOS der Hochschule Mannheim verknüpft Gerätebau und Applikationsentwicklung

On January 12, 2018, Posted by , In News, With Comments Off on Kompetenzzentrum CeMOS der Hochschule Mannheim verknüpft Gerätebau und Applikationsentwicklung

„CeMOS – Center for Biomedical Mass Spectrometry and Optical Spectroscopy” – unter diesem Titel startet das neue Kompetenzzentrum der Hochschule Mannheim zum 1. Januar 2018. Durch CeMOS, das die Aktivitäten von zwei Forschungsgruppen bündelt, werden die Forschungsschwerpunkte „Medizinische Biotechnologie/Medizintechnik“ und „Intelligente Sensorik“ der Hochschule stärker miteinander vernetzt. Die fusionierenden Forschungsgruppen,…

AbbVie’s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis

On January 9, 2018, Posted by , In News, With Comments Off on AbbVie’s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis

Breakthrough Therapy Designation is granted to investigational treatments for serious diseases with preliminary clinical evidence that the treatment may demonstrate substantial improvement over existing therapies Upadacitinib, an investigational oral agent engineered by AbbVie to selectively inhibit JAK1, is being studied as a once-daily therapy in atopic dermatitis and across multiple…

Jetzt bewerben! Innovationspreis der BioRegionen 2018

On January 8, 2018, Posted by , In News, With Comments Off on Jetzt bewerben! Innovationspreis der BioRegionen 2018

Bewerbungsfrist: 18. Februar Ihre Erfindung hat Innovationskraft und Marktpotenzial? Bewerben Sie sich um einen von drei Preisen in Höhe von jeweils 2.000 € und die Aufmerksamkeit für Ihre richtungsweisende Erfindung bei den Deutschen Biotechnologietagen im April 2018 in Berlin. Der Arbeitskreis der BioRegionen Deutschlands zeichnet zum 11. Mal herausragende Ideen aus…

Merck: FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

On January 8, 2018, Posted by , In News, With Comments Off on Merck: FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage1,2 Javelin Renal clinical development program is ongoing, including Phase III first-line study Darmstadt, Germany, and New York, US, December 21, 2017 – Merck and…

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

On January 8, 2018, Posted by , In News, With Comments Off on Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas New technology allows better testing and monitoring of HIV patients living in remote settings For the first time, patient plasma samples no longer need refrigeration during transport to the lab Card…

BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH to Create a New Global Leader in Metabolomics and Early Disease Detection

On January 8, 2018, Posted by , In News, With Comments Off on BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH to Create a New Global Leader in Metabolomics and Early Disease Detection

Innsbruck, Austria – January 3rd, 2018 – BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, announced today the acquisition of Metanomics Health GmbH. Metanomics Health is a metabolomics biomarker development and healthcare services specialist based in Berlin, Germany. At the same time, the company is closing a significant…

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

On January 8, 2018, Posted by , In News, With Comments Off on Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

New partnership will focus on discovering and developing novel treatment options for Crohn’s disease and Ulcerative colitis Orally available novel Locked Nucleic Acid (LNA) oligonucleotides technology at the core Ingelheim, Germany – 19 December, 2017 – Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and…